Clinical Oncology
Volume 22, Issue 4 , Pages 289-293, May 2010

Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?

Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK

Received 15 January 2010; received in revised form 15 February 2010; accepted 24 February 2010.

Abstract 

This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.

Key words: Adjuvant therapy, breast cancer, HER2, trastuzumab

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(10)00057-9

doi:10.1016/j.clon.2010.02.011

Clinical Oncology
Volume 22, Issue 4 , Pages 289-293, May 2010

Article Tools